Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972069 · ClinicalTrials.gov registry record · Early Phase 1
Tolerance Through Mixed Chimerism (Sip-Tego)
A Early Phase 1 study of Kidney Failure and Transplant Recipient (Kidney), sponsored by Tatsuo Kawai, MD, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06972069 is a Early Phase 1 study of Kidney Failure and Transplant Recipient (Kidney) that is actively recruiting participants, run by Tatsuo Kawai, MD, PhD. The registered enrollment target is 12 participants, below the 587-participant average among 18 other Kidney Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06972069, a Early Phase 1 study of Kidney Failure and Transplant Recipient (Kidney), is actively recruiting participants, sponsored by Tatsuo Kawai, MD, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESRD) who do not demonstrate evidence of prior sensitization.
Conditions Studied
Interventions
- PROCEDURE Combined Kidney/Bone Marrow Transplant
- PROCEDURE Donation of Kidney / Bone Marrow
- DRUG Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-31 |
| Est. Completion | 2030-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06972069
The ClinicalTrials.gov registry entry for NCT06972069 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 587-participant average among 18 other Kidney Failure trials with a reported enrollment target (98% lower). The listed sponsor is Tatsuo Kawai, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Kidney Failure appearing as the primary indexed condition, and to 3 interventions - of which Combined Kidney/Bone Marrow Transplant is the first listed.
NCT06972069 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06972069 about?
NCT06972069 is a clinical study titled "Tolerance Through Mixed Chimerism (Sip-Tego)". This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESRD) who do not demons...
What is the current status of trial NCT06972069?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-31. Estimated completion is 2030-12-31.
What conditions does trial NCT06972069 study?
This clinical trial studies the following conditions: Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation.
What interventions are being tested in trial NCT06972069?
The interventions under investigation include: Combined Kidney/Bone Marrow Transplant (PROCEDURE), Donation of Kidney / Bone Marrow (PROCEDURE), Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart) (DRUG).
Who is sponsoring clinical trial NCT06972069?
This trial is sponsored by Tatsuo Kawai, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972069 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
RECRUITING
-
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ACTIVE NOT RECRUITING
-
Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.